STERLING TO TRY AGAIN WITH A NONASPIRIN DRUG
For Sterling Drug Inc., the makers of Bayer aspirin, the recall of Johnson & Johnson's Tylenol last September presented an unexpected opportunity. Sterling had for years been trying unsuccessfully to break Tylenol's grip on the pain reliever market, and this sudden moment of vulnerability must have seemed just the right time for Sterling to try again. It was also an opportunity for the company to gain a foothold in the aspirin-free pain reliever market, something it has been refusing to attempt in recent years despite a decline in demand for aspirin products. Accordingly, analysts say, Sterling decided to introduce its Panadol drug, a nonaspirin pain reliever sold only overseas for the past 25 years, into the United States next month. ''This marks a significant change in company strategy,'' said David Crossen, an analyst at Smith Barney.